Recent Updates
Recently added Catalysts
ECOR Positive Sentiment

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Key Takeaway: electroCore, Inc. announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 11-12, 2025, in Snowbird, Utah. CEO Dan Goldberger will be hosting one-on-one meetings with investors throughout the event, encouraging engagement with potential stakeholders. The company specializes in bioelectronic medicine and is focused on using its technology platform for medical and wellness solutions.
Price reaction · baseline $16.11 (2025-02-03 close) · hit after-hours · 1 other ECOR headline(s) in the window, move may be shared
day 0 close · peak
+1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent industry conference demonstrates company initiative.
  • One-on-one meetings with CEO can lead to potential investor interest.
  • Focus on innovative bioelectronic medicine technology shows growth potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~7 mo
High dilution risk
Lead asset
GammaCore
Phase 2 · Chronic Cluster Headache

Full Press Release Details

ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12, 2025 in Snowbird, Utah.
Dan Goldberger, Chief Executive Officer, will host one-on-one meetings throughout the conference. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged out to their BTIG representative or contact the electroCore investor relations team at investors@electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.

Frequently Asked Questions

What event will electroCore participate in February 2025?

electroCore will take part in the 12th Annual BTIG MedTech Conference on February 11-12, 2025.

Who can investors contact for a meeting with Dan Goldberger?

Investors can reach out to their BTIG representative or electroCore's investor relations team.

What technology does electroCore focus on?

electroCore specializes in non-invasive vagus nerve stimulation (nVNS) technology.

What is the goal of electroCore's products?

The goal is to manage medical conditions and promote general well-being using nVNS.

Where can I find more information about electroCore?

More details can be found on electroCore's official website at www.electrocore.com.

Last updated: Feb 4, 2025